Metalloproteinase Expression in Monocytes and Macrophages and its Relationship to Atherosclerotic Plaque Instability
Abstract
Matrix metalloproteinases (MMPs) can degrade strength-giving collagens and other structural proteins of the arterial extracellular matrix. Overproduction of MMPs by monocyte/macrophages could therefore promote atherosclerotic plaque rupture and myocardial infarction. Freshly-recruited monocyte macrophages appear to use a prostaglandin (PG)-dependent pathway to coordinately upregulate a broad and potentially highly-destructive spectrum of MMPs. Differentiated macrophages rely on a series of distinct pathways to selectively upregulate groups of MMPs. Moreover, recent evidence suggests that different macrophage phenotypes express characteristically different spectra of MMPs and their inhibitors. New therapies may result from targeting matrix MMP overproduction.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Chemical resistance of NGO-crosslinked scaffolds against enzyme-mediated disruption was demonstrated by treatment with MMPs.
“Next, the chemical resistance of the NGO-crosslinked scaffolds against enzyme-mediated disruption was demonstrated by treatment with MMPs that primarily control the proteolysis of the ECM components upon transplantation12,52.”
From Bioengineered liver crosslinked with nano-graphene oxide enables efficient liver regeneration via MMP suppression and immunomodulation (2023) · cites this paper as [52]
Cited by
Sorted by citations
Monocytes in atherosclerosis: subsets and functions
Woollard, K. J., & Geissmann, F. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.228 · Cited by 890 · see citing works
Suthahar, N., Meijers, W. C., Silljé, H. H. W., & de Boer, R. A. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0343-y · Cited by 307 · see citing works
Extracellular Matrix‐Based Strategies for Immunomodulatory Biomaterials Engineering
Rowley, A. T., Nagalla, R. R., Wang, S., & Liu, W. F. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801578 · Cited by 193 · see citing works
Macrophage heterogeneity in atherosclerotic plaques
Johnson, J. L., & Newby, A. C. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283309848 · Cited by 183 · see citing works
Self-citationKim, D.-H., Kim, M.-J., Kwak, S.-Y., Jeong, J., Choi, D., Choi, S. W., Ryu, J., & Kang, K.-S. (2023) · Nature Communications · doi:10.1038/s41467-023-35941-2 · Cited by 53 · see citing works
Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease
Madonna, R., & De Caterina, R. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.02.005 · Cited by 46 · see citing works
Epigenetic regulation of key vascular genes and growth factors
Turunen, M. P., & Yla-Herttuala, S. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr109 · Cited by 41 · see citing works
Review on cardiovascular risk prediction
Ruwanpathirana, T., Owen, A., & Reid, C. M. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12110 · Cited by 31 · see citing works
- Authors
- Newby, A. C.
- Affiliations
- University of Bristol (GB)
- Corresponding author
- Newby, Andrew C.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2008-12
- Volume
- 28
- Issue
- 12
- Pages
- 2108-2114
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2167327887
- Cited by
- 496
- References
- 0
- Citations by year
- 2026: 22 · 2025: 20 · 2024: 25 · 2023: 16 · 2022: 29 · 2021: 30 · 2020: 20 · 2019: 24 · 2018: 29 · 2017: 36 · 2016: 30 · 2015: 35 · 2014: 41 · 2013: 26 · 2012: 36
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Funders
- British Heart Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- matrix metalloproteinases, monocytes, macrophages, atherosclerotic plaque instability, plaque rupture, myocardial infarction, extracellular matrix degradation, prostaglandin signaling, macrophage phenotype, matrix metalloproteinase inhibitors
- MeSH terms
- Animals, Cell Differentiation, Extracellular Matrix, Foam Cells, Humans, Macrophages, Models, Cardiovascular, Monocytes, Interleukin-4, NF-kappa B, Tissue Inhibitor of Metalloproteinases, Metalloproteases, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
